

ASX Announcement

Melbourne, Australia; 27 April 2016: Mach7 Technologies Limited (ASX:M7T) today announced an investor update presentation. This investor update follows the successful merger of Mach7 Technologies with 3D Medical Limited which completed on 8 April 2016.

The presentation which is attached to this announcement provides investors with the following information:

- Corporate overview
- Product overview
- Market overview
- Mach7 performance
- Executive team and board of director information

(presentation attached).

- ENDS

For more information, contact:

Mach7 Technologies Limited

Jenni Pilcher
CEO Australia, CFO
+61 3 9464 2222

jenni.pilcher@mach7t.com

Media (Australia)

Justin Kelly
Media and Capital Partners
+61 408 215 858

justin.kelly@mcpartners.com.au

Investor Relations (Australia)

Gabrielle Hold
Media & Capital Partners
+61 411 364 382
gabriella.hold@mcpartners.com.au

About Mach7 Technologies:

Mach7 Technologies is a global provider of enterprise image management systems that allow healthcare enterprises to easily identify, connect, and share diagnostic image and patient care intelligence where and when needed. Mach7's award-winning platform delivers image management including rapid record identification, integration, synchronisation and routing,

For personal use only

ASX Announcement

advanced clinical viewing, and optimized vendor neutral archiving. Mach7 has locations in the U.S., Asia, Australia, Africa and the Middle East. For more information, visit www.mach7t.com

Mach7's wholly-owned subsidiary, 3D Medical Limited, provides medical specific 3D printing is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. For more information, visit www.3dmedical.com.au

For personal use only

For personal use only

MACH7
TECHNOLOGIES

**INVESTOR PRESENTATION
27 APRIL 2016**

DISCLAIMER

Summary of information: This presentation contains general and background information about 3D Medical Limited (“3DM”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in 3DM nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by 3DM and all other documents provided to you by 3DM. The information in this presentation remains subject to change without notice. 3DM is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire 3DM securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. 3DM is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of 3DM securities. 3DM assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: 3DM and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of 3DM.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of 3DM. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in 3DM securities is subject to investment and other known and unknown risks, some of which are beyond the control of 3DM. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in 3DM or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in 3DM will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of 3DM.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by 3DM have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act); (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

For personal use only

CORPORATE OVERVIEW



COMPANY DESCRIPTION

In April 2016, 3D Medical (ASX:3DM) completed a merger with Mach7 Technologies™ (Mach7). The company has been renamed Mach7 Technologies Limited (**ASX.M7T**).

Mach7 is a leading global provider of enterprise image management systems and services that allow healthcare enterprises to easily identify, connect and share diagnostic image and patient care intelligence. Mach7's solutions improve patient care, compliance and clinical satisfaction.

- Corporate headquarters in Melbourne, Australia with sales, marketing, R&D and service operations based in Burlington, Vermont, USA.
- Mach7's has developed a Vendor Neutral Archive (VNA) which allows consolidation of image and document storage regardless of the underlying and disparate legacy systems the healthcare business is operating.
- This standards-based enterprise imaging solutions enables healthcare businesses to archive, consolidate, access and share medical imaging data across departments and locations.
- Mach7 has 44 customers across +200 sites, in eleven countries.

GLOBAL CUSTOMER BASE

For personal use only



Penn Medicine

44 Unique Customer

31 Hospitals

8 Imaging centres

5 Others (e.g. Telstra)

11 Countries

200 Installed sites



Montefiore



CAPITAL STRUCTURE

Mach7 has deployed over 1,000 imaging solutions at leading hospital systems in the US, Asia and the Middle East. Global success has led Mach7 to 100% revenue growth for 4 consecutive years.

CAPITAL STRUCTURE

Listed fully paid ordinary shares*	894.5m
Unlisted performance shares	300.0m
Unlisted options	121.8m
Market capitalisation (19 April)	\$66.2m
Cash (31 Dec 15 - per 4C)	\$2.1m

MAJOR SHAREHOLDERS

	% Held
BV Healthcare II Pte Ltd	9.00%
Ravindran S/O Krishnan	6.50%
Pt Dwi Satria Utama	5.30%
United Overseas Venture Sdn Bhd	5.20%
Perco Group Pty Ltd	4.60%

*~510m shares are subject to escrow conditions

MACH7 TEAM

Experienced and diverse global executive team and board of directors.

EXECUTIVE TEAM

Albert Liong (US)	MD & CEO
Jenni Pilcher (Aus)	CFO & CEO Australia
Eric Rice (US)	CTO
Ravi Krishnan (Sing)	COO & Founder

BOARD OF DIRECTORS

Ken Poutakidis (Aus)	Chairman
Albert Liong (US)	Managing Director
Damien Lim (Sing)	Non-exec
Nobuhiko Ito (Japan)	Non-exec
Nigel Finch (Aus)	Non-exec

NB: Biographies are contained in the Appendix.

*2015 Asia Pacific Medical Imaging Informatics Company of the Year
Frost & Sullivan*

For personal use only

PRODUCT OVERVIEW



A TRADITIONAL HEALTHCARE PROVIDER IT INFRASTRUCTURE

Departmental Specialty Systems (e.g. traditional data management PACS*) provide highly specialized workflow for scheduling, accessing, and diagnosing procedures.



Outputs from these systems are often **unstructured clinical media** (e.g. pictures, videos, diagnostic reports...) that are not accessible outside of the department, nor within the Enterprise EMR system.

EMR System provides for the management of **structured data** e.g. patient name, date of birth, medications, allergies,

Departmental Specialty Systems (many)



No sharing of information/images across Departments
or with EMR



Enterprise System


*Picture archiving and communication system

A MACH7 HEALTHCARE PROVIDER IT INFRASTRUCTURE

Mach7 Enterprise Imaging Platform provides for an enterprise to consolidate all unstructured clinical media (i.e. pictures, videos, diagnostic reports) across departments.

Once consolidated, the data may be made accessible from the enterprise systems such as the EMR.


Mach7 Enterprise Imaging Platform may be thought of as an EMR for all Clinical Media.



AN EVOLUTIONARY CHANGE TO PACS

DECONSTRUCTED PACS

Healthcare providers are challenged with imaging interoperability across disparate PACS. Mach7 Enterprise Imaging Platform relieves providers from the vendor locks, competition, and lack of interoperability. Mach7 deconstructs PACS by consolidating archiving and communication across an enterprise while enabling departmental picture systems (e.g. viewers) to plug into the platform.



HEALTHCARE PROVIDER BENEFITS OF CLINICAL MEDIA CONSOLIDATION

Why are Healthcare Providers consolidating departmental unstructured clinical media?

1. Enterprise Access

- Provide the ability to access all cross-departmental media from a single Electronic Medical Record.

2. Reduced Switching Costs

- Reduce future switching costs of departmental systems (i.e. PACS). Migrating data from one departmental system to another at an average sized site doing 500,000 procedures per year over 10 years could cost in excess of \$2 million USD. These future switching costs may be eliminated in the future with Mach7 Enterprise Imaging Platform.

3. Reduced Storage Costs

- Reduce storage costs with advanced compression and storage management capabilities of Mach7 Enterprise Imaging Platform.

4. Reduced Vendor Risk


- Often vendor departmental systems lock in Healthcare Providers through proprietary data formats such that the providers are unable to move to clinically superior solutions.

5. New Revenue Channels

- Through advanced unstructured data management controls, expanding revenue channels through increased specialist access can drive new revenue to Healthcare Providers.

MACH7 PRODUCT SUITE

Mach7 Enterprise Imaging Platform provides Healthcare Providers a platform to build their ecosystem of clinical applications. Both Mach7's own and third party clinical applications can be plugged into the platform for providing best-of-breed clinical care to patients.



MACH7 TECHNOLOGIES **Mach7 Enterprise Imaging Platform**
Electronic Medical Record (EMR) for Clinical Media

MACH7 AND THE COMPETITION

Based on market and customer feedback in comparison to our top competitors...

- **Effort to Solution:** 67% less effort to install and configure – unmatched technology.
- **Server Infrastructure:** 30%-50% smaller infrastructure footprint and therefore less cost to providers.
- **Management FTE:** Requires <1 FTE to manage the Mach7 solution; 60% less than our leading competitors.
- **Cost of Migrations:** Options exist to reduce migration costs by as much as 86%.

The result...

Mach7 has won 86% of opportunities within the addressable market in 2014 and 2015.

Mach 7 recognizes the need to expand the addressable market both geographically and across market segments (i.e. VNA + Enterprise PACS)

For personal use only


MARKET OVERVIEW



For personal use only

MARKET ECOSYSTEM

Substantial addressable healthcare market across multiple market segments




(1) IHS Technology, Medical Enterprise Data Storage, 2015 – Global 736m by 2019
 (2) Markets and Markets: 2013 VNA and PACS Market Report – Global 2.8bn by 2019
 (3) Frost & Sullivan: US Enterprise Medical Image Viewers Market – 715m by 2019m
 (4) HealthITAnalytics, August 5, 2015 – Global 18.7bn by 2020
 (5) Fabozzi, N. "U.S. Patient Portal Market for Hospitals and Physicians: Overview and Outlook, 2012–2017." Frost & Sullivan. 2013.
 (6) Frost & Sullivan: US Enterprise Medical Image Viewers Market

MARKET GROWTH STRATEGY

Target high procedure volume hospitals and imaging centres with high growth potential

- Focus on US market whilst developing global relationships
- Build mutually beneficial partnerships with other suppliers in healthcare
- Offer both on-premises and cloud-based solutions
- Expand addressable market – e.g. enterprise PACS solution

Total Healthcare institutions (no.) US




(1) Fast facts on US hospitals by American Hospitals Association for 2016

(2) Definitive Healthcare database on 20 Mar 2016

MARKET OPPORTUNITY

Total Global Market Size (US\$m)



(1) IHS Technology, Medical Enterprise Data Storage, 2015 – 736m by 2020
(2) Markets and Markets: 2013 VNA and PACS Market Report – 2.7bn by 2019
(3) Markets and Markets: Healthcare Content Management System Market – 440m by 2018
(4) Frost & Sullivan: US Enterprise Medical Image Viewers Market – 715m by 2019m
(5) Frost & Sullivan: US Enterprise Medical Image Viewers Market – 64m by 2017 (US only)

For personal use only

MACH7 PERFORMANCE




REVENUE MODEL

- Revenue derived from volume-based software license fees, services and annual support contracts – or pay per procedure model
- Contracts are 3-5 years, with ~80% of contract value earned upfront & upon implementation, with the balance being earned over the life of the contract
- Revenue model is evolving which provides flexibility for a range of customer budgets – e.g. upfront purchase through to pay-per-procedure

Example Pricing Model	Medium-sized Hospital	Large-sized Hospital
Term of Agreement	3-5 years	
Annual Procedures (no.)	200k	+1m
Upfront Software License Fee	\$200k	\$2m
Annual Service and Support	\$36k pa	\$360k pa

Typical 5-year contract value breakdown:



PERFORMANCE HIGHLIGHTS

Performance Metrics*	FY14	FY15	Δ%
Number of Unique Customers	31	44	+41%
Number of Employees	36	43	+19%
- Software Licence Revenue (\$ million)	\$3.6	\$4.1	+14%
- Professional Services Revenue (\$ '000)	\$275	\$838	+205%
- Support Revenue (\$ '000)	\$169	\$735	+335%
Total Revenue (\$ million)	\$4.0	\$5.7	+43%
Cash Operating Expenses (\$ million)	\$5.6	\$7.1	+31%
EBITDA Loss (\$ million)	\$1.6	\$1.4	+13%
Value of Order Book at Year End (\$ million)	\$4.7	\$9.9	+111%

*Note: Mach 7 unaudited accounts. US financial year ending December 2015. All figures USD.

For personal use only

MERGER BENEFITS

Mach7 merged with Australian-listed company 3D Medical in April 2016.

- **Product diversification**
 - Delivers on strategic plan of diversifying away from pure 'reseller' model towards IP ownership
- **Complementary businesses providing significant profitable growth opportunities**
 - Immediate access to new customer base
- **Global product offering**
 - Predominantly USA exposure with a range of healthcare IT services for developed and emerging markets
- **Increased revenue and cash flow streams driving shareholder value**
- **Strengthened executive team and know-how**

RECENT ANNOUNCEMENTS & TIMELINE

- Mach7 Merger with 3D Medical Approved by 3D Medical Shareholders
- Mach7 enters into **5-year distribution agreement** with the leading diagnostic solutions provider in South Africa, IntriHEALTH. IntriHEALTH to distribute Mach7 Enterprise Imaging Platform initially across 40 diagnostic imaging sites throughout South Africa
- Mach7 signs **5-year licence agreement with Penn State Milton S. Hershey Medical Center** - a leading academic medical centre in the U.S. with 551 beds, over 66,000 emergency visits and 29,000 surgical procedures each year
- Jenni Pilcher appointed as global CFO for Mach7 Group and CEO of Australian operations
- 3DM announces **first sale under the eUnity distribution agreement**. Five-year sales contract for the eUnity medial image viewer
- Mach7 Technologies awarded US Patent for mobile device image capture
- Mach7 has completed the **first implementation phase of its Mach7 Enterprise Imaging Platform** at Florida-based Broward Health
- Mach7 Technologies entered into a Software **Licencing Agreement with Arizona-based Yuma Regional Medical Centre**



INVESTMENT HIGHLIGHTS

- **First mover advantage with advanced IP technology**
 - Market disruptive technology, revolutionising the healthcare informatics space with impact across multiple market segments including VNA, Image Exchange, Department PACS, Enterprise PACS, ECM and Enterprise Viewers.
- **Strong order pipeline with contracted USD revenue base**
 - Multiple revenue streams from software licence, professional services and support.
- **Focused growth strategy**
 - Scalable platform with potential for substantial global growth via both sales channel and product line expansion.
- **Leadership expertise**
 - Pioneers in the field of healthcare informatics and proven track record of success.


For personal use only

APPENDICES



EXPERIENCED EXECUTIVE TEAM

Strong management team taking the company to the next level



STRONG NEW BOARD

Experienced Board with deep industry knowledge and transaction knowhow

Ken Poutakidis
Chairman
BBus

Principal of Avenue, an investment advisory firm. 15 years of Corporate Finance experience across Australia and Asia.

Prior to establishing Avenue, Mr Poutakidis worked at leading equities firms. Former Chairman of ASX:ACL

Albert Liong
Director & CEO
*BSc (Management),
MBA, CPA*

Executive management roles from finance to operations to CEO in private and public software, IT companies.

Dr Nigel Finch
Non Executive Director
*MCom, LL.M, MBA,
Ph.D, CA, CTA, FCPA,
F Fin, FTIA, FAICD*

Principal at Saki Partners Transaction Advisers.

Previously Non-Executive Director at ASX: SKB, CFO, investment manager, executive director and Associate Dean at the University of Sydney.

Damien Lim
Non Executive Director
BBA

Co-founder of Singapore-based BioVeda Capital. He has more than 21 years in equity and investment banking with Director level roles at Prime Partners, Vickers Ballas and Morgan Greenfell Asia. Serves on a number of boards as well as grant and advisory committees.

Nobuhiko Ito
Non Executive Director
BSc, MBA (Cornell)

Advisor to TPG Capital Japan. Director of Konica Minolta Business Solutions and Tadano Ltd (6395:JP).

Former President & CEO of GE Japan and executive with Exxon Chemical Japan for 16 years.

ENTERPRISE IMAGING PLATFORM LOGICAL ARCHITECTURE




Enterprise Imaging Platform

The 'A' in PACS providing...

1. Vendor Neutral Archiving
2. Storage Consolidation
3. Simplified EMR Image Enablement
4. Reduced Switching Costs – Unlock Data
5. Lifecycle Management

The 'C' in PACS providing...

1. Communication Workflow
2. Enhancing Specialty Workflows
3. Resolving PACS and Modality Limitations
4. Enabling Best-of-Breed Diagnosis
5. Automating Outside Imaging Workflow



Clinical Access & Sharing

- Universal...
- Universal Format – DICOM, JPEG, AVI...
 - Universal Platform – Windows, iOS, Android...

Zero Footprint...

- Zero Clinical Footprint – no clinical data downloaded to clients
- Zero IT Footprint – no client side installs required.



Best-of-Breed Visualization

For personal use only

THANK YOU

Contacts

Albert Liong (CEO): albert.liong@mach7t.com

Jenni Pilcher (CFO): jenni.pilcher@mach7t.com